Virax Biolabs Group Limited (VRAX)
- Previous Close
5.0600 - Open
5.2300 - Bid 4.7400 x 3800
- Ask 5.4400 x 100
- Day's Range
4.6400 - 5.5200 - 52 Week Range
0.6000 - 9.0000 - Volume
2,165,740 - Avg. Volume
5,566,436 - Market Cap (intraday)
20.234M - Beta (5Y Monthly) 1.56
- PE Ratio (TTM)
-- - EPS (TTM)
-3.3600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
viraxbiolabs.comRecent News: VRAX
View MorePerformance Overview: VRAX
Trailing total returns as of 8/30/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VRAX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VRAX
View MoreValuation Measures
Market Cap
20.67M
Enterprise Value
17.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
61.06
Price/Book (mrq)
3.85
Enterprise Value/Revenue
110.62
Enterprise Value/EBITDA
0.42
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-49.90%
Return on Equity (ttm)
-95.98%
Revenue (ttm)
156.42k
Net Income Avi to Common (ttm)
-6.73M
Diluted EPS (ttm)
-3.3600
Balance Sheet and Cash Flow
Total Cash (mrq)
3.67M
Total Debt/Equity (mrq)
4.36%
Levered Free Cash Flow (ttm)
-5.01M